A Study of the Safety and Effectiveness of JNJ-42160443 as add-on Treatment in Patients With Cancer-related Pain

Completed · Phase 2 · Has a placebo group

Conditions studied: Pain, Burning, Pain, Crushing, Pain, Migratory, Pain, Radiating, Pain, Splitting

In brief

The purpose of this study is to compare the safety and effectiveness of JNJ-42160443 with placebo in the treatment of chronic, moderate to severe cancer-related pain in terminally ill patients with a diagnosis of active cancer.

Key facts

Study ID

NCT00929188

Run by

Janssen Research & Development, LLC

People needed

100

Starts

2009-10-01

Expected to finish

2015-01-01

Last updated by the study team

2016-01-22

Who can join

Age: 18 and older, up to 99. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Terminally ill cancer patients as per judgment of the investigator (eg, patients who are in or who are candidates for hospice or palliative care for end-of-life management); Diagnosis of moderate to severe pain directly related to an active cancer that is not controlled by standard pain treatments.
• Exclusion Criteria:Planned major surgical procedures during the double-blind treatment phase that may affect study outcomes; Prior treatment with any other investigational NGF inhibitor therapy; Known allergies, hypersensitivity, or intolerance to JNJ-42160443 or its excipients; Enrolled in any investigational study within the previous 4 weeks or 5 half-lives of the investigational drug (whichever is longer), or are currently enrolled in another investigational study at the time of screening

Where it is running

• Study site — Birmingham, Alabama, United States
• Study site — Tucson, Arizona, United States
• Study site — Laguna Hills, California, United States
• Study site — Montebello, California, United States
• Study site — San Diego, California, United States
• Study site — Miami, Florida, United States
• Study site — Orlando, Florida, United States
• Study site — Stockbridge, Georgia, United States
• Study site — Anderson, Indiana, United States
• Study site — Lexington, Kentucky, United States
• Study site — Marrero, Louisiana, United States
• Study site — Shreveport, Louisiana, United States
• Study site — Farmington Hills, Michigan, United States
• Study site — Flat Rock, North Carolina, United States
• Study site — Cleveland, Ohio, United States
• Study site — Orem, Utah, United States
• Study site — Falls Church, Virginia, United States
• Study site — Lille, France
• Study site — Lyon, France
• Study site — Suresnes, France
• Study site — Toulouse, France
• Study site — Villejuif, France
• Study site — Bygdoszcz, Poland
• Study site — Gdansk, Poland
• Study site — Gdansk-Zaspa, Poland

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.